Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

NCT05275374 is registered in ClinicalTrials.gov with Xynomic Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05275374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05275374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
December 30, 2028
Enrollment
221 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, cancer, colorectal cancer, melanoma, nonsmall cell lung cancer, thyroid cancer